文献速递银屑病与炎症性皮肤病

比美吉珠单抗治疗中重度斑块状银屑病维持应答至3年:BE BRIGHT开放标签延伸试验结果

Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.
PubMed 文献 · Br J Dermatol · 2023-01-01

BE BRIGHT开放标签延伸试验汇总BE VIVID、BE READY和BE SURE三项III期研究中接受比美吉珠单抗治疗的患者数据,评估第16周应答者至治疗3年的应答维持情况。第16周达PASI 90、PASI 100、绝对PASI≤2和BSA≤1%的患者中,分别有93.0%、80.8%、94.0%和90.3%维持应答至3年(mNRI)。

要点

  • 第16周PASI 90应答者中93.0%维持PASI 90至3年(mNRI)。
  • 第16周PASI 100应答者中80.8%维持PASI 100至3年(mNRI)。
  • 第16周PASI 100应答者中DLQI 0/1应答从76.3%升至3年时89.0%(mNRI)。

核心结论

  • 绝大多数第16周应答者在比美吉珠单抗治疗3年后仍维持高水平临床应答。
  • 长期比美吉珠单抗治疗有效,并对中重度斑块状银屑病患者的健康相关生活质量有重要获益。

研究设计与样本

  • 汇总BE VIVID(52周)、BE READY和BE SURE(56周)三项III期研究中接受比美吉珠单抗治疗的患者数据,及其正在进行的开放标签延伸试验BE BRIGHT。
  • 基线随机分配至比美吉珠单抗的患者共989例。
  • 报告第16周有疗效应答的患者至比美吉珠单抗治疗3年的疗效结局。
  • 缺失数据主要采用改良无应答者填补(mNRI),同时报告无应答者填补和观测病例数据。

主要发现

  • 第16周时,693例达PASI 90、503例达PASI 100、694例达绝对PASI≤2、597例达BSA≤1%,并继续进入开放标签延伸试验。
  • 上述第16周应答者中,93.0%维持PASI 90、80.8%维持PASI 100、94.0%维持PASI≤2、90.3%维持BSA≤1%应答至比美吉珠单抗治疗3年(mNRI)。
  • 第16周PASI 90应答者中,96.8%和72.5%在第16周分别达IGA 0/1和PASI 100,第3年时分别有92.2%和73.4%达这些应答(mNRI)。
  • 第16周PASI 100应答者中,76.3%在第16周达DLQI 0/1,随持续比美吉珠单抗治疗DLQI 0/1应答至第3年升至89.0%(mNRI)。

关键数值与推荐

  • 第16周PASI 90应答者维持PASI 90至3年:93.0%(mNRI)。
  • 第16周PASI 100应答者维持PASI 100至3年:80.8%(mNRI)。
  • 第16周绝对PASI≤2应答者维持PASI≤2至3年:94.0%(mNRI)。
  • 第16周BSA≤1%应答者维持BSA≤1%至3年:90.3%(mNRI)。
  • 第16周PASI 100应答者DLQI 0/1应答:第16周76.3% vs 第3年89.0%(mNRI)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given the chronic nature of psoriasis and the loss of response that can be observed with therapies over time, it is important to understand the long-term efficacy of new treatments. OBJECTIVES: To evaluate maintenance of Week 16 responses with bimekizumab (BKZ) treatment through Year 3, in patients with moderate-to-severe plaque psoriasis. METHODS: Data were pooled from BKZ-treated patients in the 52-week (BE VIVID) and 56-week (BE READY and BE SURE) phase III studies, and their ongoing open-label extension (OLE), BE BRIGHT. Efficacy outcomes are reported through 3 years of BKZ treatment in patients with an efficacy response at Week 16. Missing data were imputed primarily using modified nonresponder imputation (mNRI), with nonresponder imputation and observed case data also reported. RESULTS: A total of 989 patients were randomized to BKZ at baseline in BE VIVID, BE READY and BE SURE. At Week 16, 693 patients achieved ≥ 90% reduction from baseline in Psoriasis Area and Severity Index (PASI 90), 503 achieved 100% reduction from baseline in PASI (PASI 100), 694 achieved absolute PASI ≤ 2 and 597 achieved body surface area (BSA) ≤ 1%, and continued into the OLE. Of these, 93.0% maintained PASI 90, 80.8% maintained PASI 100, 94.0% maintained PASI ≤ 2 and 90.3% maintained BSA ≤ 1% responses through to 3 years of BKZ treatment (mNRI). Among Week 16 PASI 90 responders, 96.8% and 72.5% also achieved Investigator's Global Assessment 0/1 and PASI 100 at Week 16, respectively, and 92.2% and 73.4% achieved these responses at Year 3 (mNRI). Among Week 16 PASI 100 responders, 76.3% also achieved Dermatology Life Quality Index (DLQI) 0/1 at Week 16, and DLQI 0/1 response increased with continuous BKZ treatment to 89.0% at Year 3 (mNRI). CONCLUSIONS: High levels of clinical response were maintained through to 3 years of BKZ treatment in the vast majority of Week 16 responders. Long-term treatment with BKZ was efficacious, with important benefits for health-related quality of life, in patients with moderate-to-severe plaque psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Strober B, Tada Y, Mrowietz U, et al. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. Br J Dermatol. 2023. PMID: 36967713. doi:10.1093/bjd/ljad035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。